Hepatorenal Syndrome Treatment Market Report 2025

The hepatorenal syndrome treatment market size has grown strongly in recent years. It will grow from $14.49 billion in 2024 to $15.31 billion in 2025 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to automotive industry growth, aerospace sector requirements, advantages in material utilization, improved mechanical properties, stringent industry standards, efficiency and precision gains.

The hepatorenal syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $19.94 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to rise in renewable energy projects, growing demand for high-performance alloys, focus on sustainable manufacturing, expansion of oil and gas exploration, demand for high-performance components. Major trends in the forecast period include integration of industry 4 technologies, research and development in forging techniques, customization for specific applications, automation in forging processes, innovations in heating and cooling technologies.

The rising incidence of patients with liver damage or cirrhosis is expected to drive the growth of the hepatorenal syndrome treatment market in the coming years. Cirrhosis is a serious liver disease characterized by the permanent replacement of healthy liver tissue with scar tissue. Treatment for hepatorenal syndrome focuses on preserving kidney function while alleviating the symptoms and negative effects of the condition. These strategies can enhance overall health and improve eligibility for liver transplant surgery. For example, a report published in July 2023 by the British Liver Trust, a UK-based charity organization, revealed that hospital admissions for liver disease in England increased by 22% in just one year, rising from 67,458 in 2021 to 82,290 in the financial year ending in 2022. Consequently, the increase in cases of liver damage or cirrhosis is driving the growth of the hepatorenal syndrome treatment market.

The increasing number of fast-track and novel drug designations is expected to drive the growth of the hepatorenal syndrome treatment market in the future. Fast-track and novel drug designations are regulatory pathways designed to accelerate the development, review, and approval of drugs for serious conditions with unmet medical needs, facilitating quicker access to innovative therapies for patients. The rise in these designations aims to expedite the development of treatments for hepatorenal syndrome by addressing the urgent need for effective therapies, potentially enhancing patient outcomes and fulfilling unmet medical needs associated with this condition. For example, a report from the Food and Drug Administration (FDA), a U.S. regulatory agency, stated that in 2022, 37 new drugs, known as novel drugs, were approved, which had never before been approved or marketed in the U.S. Among these, the Center for Drug Evaluation and Research (CDER) granted approvals for 28 (76%) during their first review cycle. Thus, the rise in fast-track and novel drug designations is propelling the growth of the hepatorenal syndrome treatment market.

An increase in healthcare spending is projected to drive the growth of the hepatorenal syndrome treatment market in the coming years. Healthcare spending encompasses the total expenditures on healthcare across all sectors of an economy, including hospitals, home health services, prescription drugs, nursing homes, and individual healthcare. As healthcare spending increases, more resources may be allocated to the research and development of innovative and more effective treatments for hepatorenal syndrome (HRS). Additionally, higher spending could lead to improved availability of tools for HRS screening and early detection, which may facilitate earlier interventions and better patient outcomes. For instance, a report from the Office for National Statistics, a UK-based government department, indicated that total healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of just 0.9% in 2022. Therefore, the rise in healthcare spending is a significant factor driving the growth of the hepatorenal syndrome treatment market.

A prominent trend in the hepatorenal syndrome treatment market is the increasing focus on research and development activities. Companies operating in this market are intensifying their efforts in research and development to maintain their market positions. For example, Mallinckrodt Pharmaceuticals, in September 2022, received FDA approval for Terlivaz, an injection to help adults with hepatorenal syndrome's kidney function, supported by the Phase 3 CONFIRM trial. This emphasis on research and development is vital for advancing treatment options for hepatorenal syndrome, resulting in improved patient outcomes.

Major companies in the hepatorenal syndrome treatment market are strategically focusing on advanced products such as hepatorenal drug solutions to enhance patient outcomes and address unmet medical needs. Hepatorenal drug solutions refer to innovative pharmaceuticals or treatments specifically designed to target and address the intricate pathology of hepatorenal syndrome. For instance, Ocelot Bio Inc., in August 2022, received orphan drug designation for its lead candidate OCE-205, addressing the urgent unmet medical needs of hepatorenal syndrome patients through a distinct mechanism of action. This strategic focus on advanced solutions contributes to improved efficacy and better management of hepatorenal syndrome, offering hope to patients with this complex condition affecting the liver and kidneys.

Major companies operating in the hepatorenal syndrome treatment market include BioVie Inc., Cumberland Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Orphan Therapeutics LLC, Baxter International Inc., La Jolla Pharmaceutical Company, Noorik Biopharmaceuticals AG, Novartis AG, Zydus Lifesciences Limited, Ocelot Bio Inc., New Medicon Pharma Lab Private Limited, Arrowhead Pharmaceuticals, Stealth BioTherapeutics Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, Catalyst Pharmaceuticals Inc., Bayer AG, Gilead Sciences Inc.

North America was the largest region in the hepatorenal syndrome treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global hepatorenal syndrome treatment market during the forecast period. The regions covered in the hepatorenal syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hepatorenal syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Hepatorenal syndrome (HRS) is a multiorgan disorder characterized by acute kidney injury in patients with severe liver disease. Individuals with this syndrome exhibit signs and symptoms of liver failure along with reduced urine output, leading to oliguria.

The main types of hepatorenal syndrome treatment include type 1 hepatorenal syndrome and type 2 hepatorenal syndrome. Type 2 hepatorenal syndrome is characterized by a moderate and steady decline in glomerular filtration rate and commonly affects individuals whose liver function is still predominantly intact. Treatment involves the administration of therapeutics and, in some cases, surgical interventions. These treatments are utilized across various end-users, including hospitals and clinics, ambulatory surgical centers, academic and research institutes, among others.

The hepatorenal syndrome treatment market research report is one of a series of new reports that provides hepatorenal syndrome treatment optical components market statistics, including hepatorenal syndrome treatment optical components industry global market size, regional shares, competitors with a hepatorenal syndrome treatment optical components market share, detailed hepatorenal syndrome treatment optical components market segments, market trends and opportunities, and any further data you may need to thrive in the hepatorenal syndrome treatment optical components industry. This hepatorenal syndrome treatment optical components market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hepatorenal syndrome treatment market includes revenues earned by providing imaging, blood, and urine tests to evaluate the patient's liver and kidney function. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.